Clinical Trial Update: Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, and the body's ability to develop resistance to an investigational shingles vaccine (V211-007); the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• V211-007

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Shingles | Phase 2 | Status: COMPLETED